Prognosis
Sinovac Provides Inadequate Shield Against Omicron in Hong Kong Study
- Chinese shot is one of the most widely used globally
- Three doses can neutralize omicron better: Sinovac study
This article is for subscribers only.
The vaccine made by Sinovac Biotech Ltd., one of the most widely used in the world, doesn’t provide sufficient antibodies in two doses to neutralize the omicron variant and boosters will likely be needed to improve protection, initial lab findings showed.
While the first two studies to be released on the Chinese shot and omicron diverged on how much the vaccine’s immune response is degraded, they both indicated the standard two-dose course would not be enough, raising uncertainty over a shot relied on by millions of people in China and the developing world to protect against Covid-19.